Research Tracker›Biomarker Atlas›Epilepsy›S100B

S100B in Epilepsy

S100B belongs to the neurological group of Epilepsy markers and is reported to be raised relative to the reference group of the cited comparison (epileptic patients vs healthy controls). The source does not tie this marker to a specific symptom cluster, so it is best read as a biological signal rather than a symptom predictor. The finding is drawn from Simani et al. 2020; it describes group-level differences, not a threshold that classifies an individual.

↑ ElevatedNeurological

Summary

Direction in Epilepsy↑ Elevated — higher than in the comparison group
CategoryNeurological
Compared againstepileptic patients vs healthy controls
SourceSimani et al. 2020 — doi:10.1021/acschemneuro.0c00492
Condition atlasEpilepsy Biomarker Atlas

Other conditions where S100B is reported

See the cross-condition hub: S100B across conditions.

Related Neurological markers in Epilepsy

Full list: Epilepsy Biomarker Atlas.

Frequently asked questions

Is S100B high or low in Epilepsy?

Elevated. Studies summarised in the OSMF atlas report higher S100B in Epilepsy than in the reference group of the cited comparison (epileptic patients vs healthy controls). Source: Simani et al. 2020.

Which test measures S100B?

The atlas record does not list a standardised clinical test code (LOINC) for S100B, which usually means it was measured with research assays or study-specific protocols rather than a routine clinical panel. Check the cited source for the exact method.

Is one abnormal S100B result diagnostic of Epilepsy?

No. No single biomarker is diagnostic of Epilepsy. S100B findings come from group comparisons, overlap considerably between patients and controls, and vary with study design, timing and comparison group. A result should be interpreted by a clinician alongside symptoms, history and other tests.

Is S100B specific to Epilepsy?

No. The same marker is also reported in Gulf War Illness, Long COVID in this atlas, so it reflects shared biology (for example inflammation or vascular stress) rather than a condition-specific signature.

Cite this page

Open Source Medicine Foundation. (2026). S100B in Epilepsy: direction, evidence and what it means. OSMF Research Tracker. Retrieved October 7, 2026, from https://research.opensourcemed.info/biomarkers/epilepsy/s100b.html
Get OSMF research updates. New biomarker, trial and treatment evidence summaries by email.
Subscribe on Substack

Last reviewed: 2026-07-03 · Page generated from epilepsy.json · Browse: Epilepsy atlas · Biomarker Index · All marker pages

Disclaimer: This page is an educational synthesis of published, peer-reviewed research and is not medical advice. Biomarker findings vary across studies with case definitions, comparison groups, timing and assay methods. Direction of change reflects the predominant finding in the cited source and does not establish a diagnostic threshold. Discuss any test result with a qualified clinician.